Comparing SGLT2 Inhibitors on Incident Major Adverse Kidney Events in Type 2 Diabetes: A Target Trial Emulation
Two of three SGLT2 inhibitors showed modest but measurable protection against serious kidney complications in type 2 diabetes.
This target-trial emulation using weighted retrospective claims cohorts examined Comparing SGLT2 Inhibitors on Incident Major Adverse Kidney Events in Type 2 Diabetes: A Target Trial Emulation. Dapagliflozin and empagliflozin were associated with modestly fewer major adverse kidney events than canagliflozin.
What the study was
- Study design
- Target-trial emulation using weighted retrospective claims cohorts
- Population
- Adults with type 2 diabetes at moderate cardiovascular risk without stage 3 or worse chronic kidney disease
- Sample size
- 131,434 weighted initiators
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Mayo Clinic proceedings
Why it surfaced
Target-trial emulation using weighted retrospective claims cohorts; Dapagliflozin and empagliflozin were associated with modestly fewer major adverse kidney events than canagliflozin. Score kept conservative because only the PubMed abstract and metadata were reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.